Adjuvant chemotherapy in early breast cancer: Optimal and suboptimal anthracycline-containing regimens

Breast Cancer Research and Treatment

Volumn 80, Issue 3, 2003, Pages 313-320

  Cocconi, Giorgio ^a,b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b NONE   (Italy)

Author keywords

Adjuvant chemotherapy; Anthracycline; Anthracycline containing regimens; Breast carcinoma; CMF; Early breast carcinoma; Overview

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN C; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041823460     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024955408785     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 352: 930-942, 1998
2. Thompson SG: Why sources of heterogeneity in meta-analyses should be investigated. BMJ 309: 1351-1355, 1994
3. Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, Sass R, Fisher ER, Jochisem P, Legault-Poisson S, Dimitrov N, Wolter J, Bornstein R, Elias EG, LiCalzi N, Paterson AHG, Sutherland CM: Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7: 572-582, 1989
4. De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, Marinelli A, De Laurentiis M, Variale E, Putrella G, Gallo C, Bianco AR: CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer 71: 1283-1287, 1995
5. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9: 1124-1130, 1991
6. Bianco AR, Costanzo R, Di Lorenzo G, Adamo V, Altavilla G, D'Aprile M, Palazzo SZ, Manzione L, Farris A, De Lena M: The Mam-1 GOCSI trial: a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node-positive (N+) early breast cancer. Proceed ASCO 20: 27a, 2001 (abstract)
7. Beuzeboc P, Mosseri V, Scholl S, Dorval T, Garcia Giralt E, Jouve M, Palangie T, Pouillart P: Adriamycin based combination chemotherapy significantly improves overall survival in high risk premenopausal breast cancer patients. Breast Cancer Res Treatment 11: 166, 1991 (abstract)
8. Budd GT, Green S, O'Brian RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O'Sullivan J, Osborne CK: Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin Oncol 13: 831-839, 1995
9. Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 14: 1136-1145, 1996
10. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INT 0102. Proceed ASCO 17: 1a, 1998 (abstract)
11. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16: 2651-2659, 1998
12. Mouridsen HT, Andersen J, Andersson M, Dombernowsky P, Ejilertsen B, Rose C, Sorensen PG, Sandberg E, Andersen KW, Jensen MB, Bengston NO, Bergh J, Nordenskjold B: Adjuvant anthracycline in breast cancer improves outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proceed ASCO 18: 68a, 1999 (abstract)
13. Carpenter JT, Velez-Garcia E, Aron BS, Salter M, Stahl DL, Estes N, Stagg M, Bartolucci A, Singh KP: Five year results of a randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) for node-positive breast cancer. Proceed ASCO 13: 66, 1994 (abstract)
14. Coombes RC, Bliss JM, Wils J, Marvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-Lopez FR, Vassilopoulos P, Pinto Ferriera E, Chilvers CED, Coombes G, Woods EM, Marty M: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopasual women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 14: 35-45, 1996
15. Martin M, Villar A, Solé-Calvo A, Gonzalez R, Massuti B, Munarriz B, Lizon J, Camps C, Carrato A, Casado A, Candel M, Albanell J, Aranda E, Campbell J: FAC versus CMF as adjuvant treatment for operable breast cancer: a GEICAM study. Proceed ASCO 20: 32a, 2001 (abstract)
16. Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Rosa Bian A, Rodino C, Rondini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M: Epirubicin vs CMF as adjuvant therapy of stage I and II breast cancer: a prospective randomised study. Eur J Cancer 38: 2279-2288, 2002
17. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Walter J, Wozniak T, Fisher ER, Deutsch M: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483-1496, 1990
18. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92: 1991-1998, 2000
19. Fisher B, Anderson S, Tan-Chiu, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19: 931-942, 2001
20. Pribylova O, Petruzelca L, Honova H, Fischer J, Bustova I, Siffnerova H, Kuta M, Miller V, Hacklova M, Machacek J, Kohoutek M, Vodvarka P, Kysela T, Tajblova J, Suk J, Dorazilova V, Bauer J: Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study. Sb Lek 99:25-31, 1998
21. Galligioni E, Cetto G, Nascinben O, Buonadonna A, Crivellari D, Molino A, Veronesi A, Graiff C, Barni S, Puccetti C, Ferrazzi E, Recaldin E, Sava C, Saracchini S, Sacco C: Adjuvant chemotherapy with high-dose epirubicin and cyclophosphamide (EC) versus cyclophosphamide, methotrexate, fluorouracil (CMF) in high risk premenopausal breast cancer patients (pts). A prospective randomized trial. Proceed ASCO 16: 145a, 1997 (abstract)
22. Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Durane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103-3110, 2001
23. Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh Dy, Choe KJ, Bang YJ, Kim SR, Kim NK: Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Results of a randomized controlled trial. Cancer 89: 2521-2526, 2000
24. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994
25. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Adgerton S, Allred C, Norton L, Liu ET: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
26. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998